Secondary amyloidosis other imaging findings
|
Secondary amyloidosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Secondary amyloidosis other imaging findings On the Web |
|
American Roentgen Ray Society Images of Secondary amyloidosis other imaging findings |
|
Risk calculators and risk factors for Secondary amyloidosis other imaging findings |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Shyam Patel [2]Associate Editor(s)-in-Chief: Sahar Memar Montazerin, M.D.[3]
Overview
Total body SAP component scintigraphy may be used in the workup and follow-up of patients with amyloid deposition. This method has been observed to have high sensitivity (90%) and requires a low radioactive dose which makes it a safe and effective method. The radiolabeled SAP binds to aa amyloid and localizes its deposition semiquantitatively.
Other Imaging Findings
Total Body SAP Scintigraphy
- Total body SAP component scintigraphy may be used in the workup and follow-up of patients with amyloid deposition.[1][2]
- This method has been observed to have high sensitivity (90%) and requires a low radioactive dose which makes its usage safe and effective.
- The radio labeled SAP binds to aa amyloid and localizes its deposition semi quantitatively.[3]
- However, this imaging modality is unable to identify deposits in hollow, diffuse, or small structures, such as the gastrointestinal tract, skin, and nerves.
- Also, SAP scintigraphy is unable to detect cardiac and lung involvement due to movement and blood content of these organs.
- Given the rarity of cardiac involvement in aa amyloidosis, an staging systems using cardiac imaging or biomarkers is not validated for detection of aa amyloid deposition in heart.
- Additionally, uremic cardiomyopathy is not distinguishable from amyloid deposition and cardiac magnetic resonance is relatively contraindicated in patients with secondary amyloidosis due to advanced renal disease.
References
- ↑ Hawkins, Philip N. (2002). "Serum amyloid P component scintigraphy for diagnosis and monitoring amyloidosis". Current Opinion in Nephrology and Hypertension. 11 (6): 649–655. doi:10.1097/00041552-200211000-00013. ISSN 1062-4821.
- ↑ Hazenberg, Bouke P.C.; van Rijswijk, Martin H.; Piers, D. Albertus; Lub-de Hooge, Marjolijn N.; Vellenga, Edo; Haagsma, Elizabeth B.; Hawkins, Philip N.; Jager, Pieter L. (2006). "Diagnostic Performance of 123I-Labeled Serum Amyloid P Component Scintigraphy in Patients with Amyloidosis". The American Journal of Medicine. 119 (4): 355.e15–355.e24. doi:10.1016/j.amjmed.2005.08.043. ISSN 0002-9343.
- ↑ Papa, Riccardo; Lachmann, Helen J. (2018). "Secondary, AA, Amyloidosis". Rheumatic Disease Clinics of North America. 44 (4): 585–603. doi:10.1016/j.rdc.2018.06.004. ISSN 0889-857X.